EAST SETAUKET, N.Y., May 25, 2011 /PRNewswire/ -- John S. Kovach, M.D., Chair, Board of Directors and CEO of Lixte Biotechnology Holdings, Inc. (LIXT.PK), announces the appointment of Robert B. Royds, M.B., B.S., M.R.C.P. to the company's Board of Directors.
Dr. Royds is Chair of the Board and Medical Director of Theradex Systems, Inc., a leading clinical research organization, which he founded in 1982. Theradex®, based in Princeton, NJ, with research bases in Europe, Australia, and Japan, provides a full complement of services critical to drug development including regulatory strategy, consulting, pre-clinical toxicology and pharmacology review, preparation of regulatory filings, and clinical trials design. Dr. Royds is responsible for the scientific affairs of the company.
Trained in internal medicine and pharmacology, Dr. Royds has extensive experience in all stages of clinical drug development process. Before founding Theradex®, he was Senior Research Physician at Hoffmann-La Roche, Inc., and Associate Director for Clinical Pharmacology International at Merck, Sharp, and Dohme Research Laboratories. He has been a consultant/advisor to the National Institute of Child Health and Development and the National Cancer Institute on issues of clinical trial design and international standardization of data sets of clinical trials of new investigational anti-cancer agents. He has served as the physician-monitor for the Clinical Trials Monitoring Service of the National Cancer Institute since 1979, and has been the Principal Investigator for this contract since 1982.
"We are extremely pleased that Dr. Royds has joined our Board of Directors. He has had an exceptional experience in all aspects of cancer drug development, especially in the increasingly complex area of efficient clinical evaluation of new anti-cancer drugs with diverse clinical applications," said Dr. Kovach. "Dr. Royds' expertise i
|SOURCE Lixte Biotechnology Holdings, Inc.|
Copyright©2010 PR Newswire.
All rights reserved